Effect of hepatic and renal dysfunction on disposition of Bupropion in rats

Juzar S. Kaka, Khalil I. Al-Khamis, Musbah O M Tanira

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve upto 6 h (AUC 0-6) and AUC 0-∞ increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-∞ of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume13
Issue number3
DOIs
Publication statusPublished - Jul 1988

Fingerprint

Bupropion
Area Under Curve
Kidney
Liver
Half-Life
Gentamicins
Carbon Tetrachloride
Pharmaceutical Preparations
Biological Availability
Oral Administration

Keywords

  • enal dysfunction
  • epatic damage
  • rats
  • upropion

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of hepatic and renal dysfunction on disposition of Bupropion in rats. / Kaka, Juzar S.; Al-Khamis, Khalil I.; Tanira, Musbah O M.

In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 13, No. 3, 07.1988, p. 149-153.

Research output: Contribution to journalArticle

@article{1278aaedc3594322b1389f887cbe6563,
title = "Effect of hepatic and renal dysfunction on disposition of Bupropion in rats",
abstract = "Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve upto 6 h (AUC 0-6) and AUC 0-∞ increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-∞ of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.",
keywords = "enal dysfunction, epatic damage, rats, upropion",
author = "Kaka, {Juzar S.} and Al-Khamis, {Khalil I.} and Tanira, {Musbah O M}",
year = "1988",
month = "7",
doi = "10.1007/BF03189933",
language = "English",
volume = "13",
pages = "149--153",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - Effect of hepatic and renal dysfunction on disposition of Bupropion in rats

AU - Kaka, Juzar S.

AU - Al-Khamis, Khalil I.

AU - Tanira, Musbah O M

PY - 1988/7

Y1 - 1988/7

N2 - Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve upto 6 h (AUC 0-6) and AUC 0-∞ increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-∞ of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.

AB - Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve upto 6 h (AUC 0-6) and AUC 0-∞ increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-∞ of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.

KW - enal dysfunction

KW - epatic damage

KW - rats

KW - upropion

UR - http://www.scopus.com/inward/record.url?scp=0023691940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023691940&partnerID=8YFLogxK

U2 - 10.1007/BF03189933

DO - 10.1007/BF03189933

M3 - Article

VL - 13

SP - 149

EP - 153

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

IS - 3

ER -